traumatic brain injury (tbi)

MTOB (α-keto-γ-Methylthiobutyric acid) is a substrate for c-terminal binding protein (CtBP) that interferes with the carcinogenic activity of CtBP in cell culture and mice. It also actively regulates TCF-4 signaling, leading to cancer stem cell (CSC) growth and self-renewal.

HEPPS exhibits inhibitory activity against the amyloid-beta precursor protein, reducing Aβ aggregation burden and improving neuronal autophagy flux, thereby alleviating neuronal apoptosis and traumatic brain injury (TBI) in mice. It can be used for research into Alzheimer's disease and neurological disorders.

Candesartan (CV 11974) is an angiotensin II receptor blocker widely used in the treatment of hypertension and heart failure.

P7C3 is a class of neuroprotective aminopropyl carbazoles which has been shown to block neuronal cell death in models of neurodegeneration. It was shown that P7C3 molecules additionally preserve axonal integrity after injury, before neuronal cell death occurs, in a rodent model of blast-mediated traumatic brain injury (TBI). This protective quality may be linked to the ability of P7C3 molecules to activate nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in nicotinamide adenine dinucleotide salvage.

Neuroprotective agent 12 is an orally active compound capable of crossing the blood-brain barrier, offering significant neuroprotective properties. It exhibits robust antioxidant and anti-inflammatory effects, markedly inhibiting cell death induced by glutamate and acrolein. This agent reduces the expression of PDE4B while elevating levels of HO-1, p-CREB, and BDNF. In a traumatic brain injury (TBI) mouse model, Neuroprotective agent 12 demonstrates potent neuroprotection and holds potential for research into TBI and other central nervous system disorders.

IRF1 antagonist 1 (8003-3282) is a potent antagonist of IRF1 (interferon regulatory factor), exhibiting anti-inflammatory properties. This compound helps maintain the integrity of the blood-brain barrier and reduces cerebral edema. Additionally, IRF1 antagonist 1 can enhance neurological outcomes in mouse models of acute traumatic brain injury (TBI).

FeTPPS, a decomposition catalyst for 5,10,15,20-tetrakis(4-sulfonatophenyl) porphyrin iron(III) chloride peroxynitrite, exhibits marked neuroprotective effects in experimental spinal cord injury models. It reduces cerebral tissue inflammation and damage, inhibits nitric oxide production and apoptosis, and may be employed in traumatic brain injury (TBI) research.

RX 801077 is a highly selective alpha2-adrenoceptor antagonist. It enhances norepinephrine release in the synapse, used for depression, cognitive impairment, and CNS pharmacology research.

PNT001 is a human IgG1 monoclonal antibody (mAb) targeting cis-pT231 Tau. It is applicable for research in neurodegenerative diseases and traumatic brain injury (TBI). The recommended isotype control is Human IgG1 kappa, Isotype Control.

Biotin-COG1410 TFA is a biotinylated form of COG1410. COG1410 is a derivative peptide of apolipoprotein E and acts as an inhibitor of apoptosis. It exhibits neuroprotective and anti-inflammatory effects in a mouse traumatic brain injury (TBI) model. COG1410 is applicable for research in neurological disorders.

Neuron-specific enolase, Human (EC 4.2.1.11), is an enolase enzyme that serves as a biomarker for traumatic brain injury (TBI), stroke following cardiac arrest, hypoxic encephalopathy, and acute spinal cord injury (SCI).